Valuation: Assembly Biosciences, Inc.

Market Cap 404M 361M 333M 302M 565M 38.35B 574M 4.01B 1.59B 20.09B 1.52B 1.48B 63.34B P/E 2026 *
-170x
P/E 2027 * -7.27x
Enterprise Value 317M 284M 262M 237M 444M 30.14B 451M 3.15B 1.25B 15.79B 1.19B 1.17B 49.78B EV / Sales 2026 *
5.01x
EV / Sales 2027 * 8.12x
Free-Float
72.34%
Yield 2026 *
-
Yield 2027 * -
10-05 Assembly Biosciences, Inc. Presents Positive Phase 1a Safety, Tolerability And Target Engagement Data For ABI-6250 At AASLD The Liver Meeting CI
10-05 Assembly Biosciences Plans to Present Posters Featuring New Phase 1a Data From ABI-6250 Program MT
09-21 Assembly Biosciences, Inc.(NasdaqGS:ASMB) added to S&P Biotechnology Select Industry Index CI
09-08 Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead MT
09-08 Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead DJ
09-08 Assembly Biosciences, Inc. and Gilead Sciences, Inc. Exercise U.S. Profit-Share Option for HSV Helicase-Primase Inhibitor Program CI
09-01 UBS Initiates Assembly Biosciences at Buy With $52 Price Target MT
08-21 Certain Common Stock of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-21 Certain Pre-Funded Warrants of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-21 Certain Stock Options of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-21 Certain Restricted Stock Units of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-21 Certain Performance Stock Units of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. CI
08-13 Assembly Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
1 day-2.17%
1 week-1.24%
Current month-15.54%
1 month-16.18%
3 months-22.35%
6 months-28.81%
Current year-41.66%
1 week 19.3
Extreme 19.3
21.93
1 month 19.3
Extreme 19.3
23.86
Current year 19.3
Extreme 19.3
37.01
1 year 19.3
Extreme 19.3
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
39.7
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 31/12/2022
Director of Finance/CFO - 04/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 03/06/2026
Director/Board Member 61 13/12/2017
Director/Board Member 68 05/08/2019
Date Insider Type Main position Quantity % Market Cap. Importance
04/06/26 Free

Director

8,000 0.0514%
04/06/26 Free

Director

8,000 0.0514%
04/06/26 Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%-1.24%-32.15%+98.77% 404M
+2.41%+0.29%+39.41%+73.38% 64.69B
-0.15%+7.50%+11.42%+75.22% 54.78B
+0.57%+4.60%+7.71%+100.57% 53.49B
+0.37%+4.67%+26.68%+54.16% 45.98B
-1.21%+2.32%+21.50%+126.83% 42.94B
-0.37%+5.07%+243.23%+834.48% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
-1.22%-9.33%+21.73%+1.98% 23.97B
-0.38%+5.68%+38.39%+29.86% 23.67B
Average -0.18%+2.05%+39.60%+144.38% 38.35B
Weighted average by Cap. +0.26%+2.73%+45.65%+151.36%

Financials

2026 *2027 *
Net sales 63.43M 56.64M 52.33M 47.42M 88.72M 6.02B 90.18M 630M 249M 3.15B 238M 233M 9.95B 34.12M 30.47M 28.15M 25.51M 47.72M 3.24B 48.51M 339M 134M 1.7B 128M 125M 5.35B
Net income 1.4M 1.25M 1.16M 1.05M 1.96M 133M 2M 13.93M 5.52M 69.79M 5.27M 5.15M 220M -56.83M -50.75M -46.89M -42.49M -79.49M -5.4B -80.81M -564M -223M -2.83B -213M -209M -8.91B
Net Debt -86.48M -77.23M -71.34M -64.65M -121M -8.21B -123M -859M -340M -4.3B -325M -318M -13.56B -127M -113M -105M -94.86M -177M -12.04B -180M -1.26B -499M -6.31B -476M -466M -19.9B
Projected Income Statement - Annual - Assembly Biosciences, Inc.
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
23/10/26 US$19.84 -2.17% 206,013
22/10/26 US$20.28 -0.88% 137,849
21/10/26 US$20.46 -3.45% 234,769
20/10/26 US$21.19 +5.11% 222,797
19/10/26 US$20.16 +0.35% 199,155
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Assembly Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
19.84USD
Average target price
52.00USD
Spread / Average Target
+162.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Assembly Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. ASMB Stock